Observational studyHaematologica2024

Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer.

Cornelia Englisch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.